A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
A Phase 1, First-in-Human Study of CUSP06, a Cadherin-6 (CDH6)-Directed Antibody-Drug Conjugate, in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
Sponsor: OnCusp Therapeutics, Inc.
This PHASE1 trial investigates Ovarian Cancer and Solid Tumor and is currently actively recruiting participants. OnCusp Therapeutics, Inc. leads this study, which shows 11 recorded versions since 2024 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE1
-
Nov 2025 — Feb 2026 [monthly]
Recruiting PHASE1
-
Jun 2025 — Nov 2025 [monthly]
Recruiting PHASE1
-
Apr 2025 — Jun 2025 [monthly]
Recruiting PHASE1
-
Sep 2024 — Apr 2025 [monthly]
Recruiting PHASE1
▶ Show 6 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE1
-
May 2024 — Jun 2024 [monthly]
Recruiting PHASE1
-
Apr 2024 — May 2024 [monthly]
Recruiting PHASE1
-
Mar 2024 — Apr 2024 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Feb 2024 — Mar 2024 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- OnCusp Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .